U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                   Form 10-QSB

                QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended:   June 30, 2001

Commission file no. 0-24921

                         Surgical Safety Products, Inc.
                  --------------------------------------------
                 (Name of small business issuer in its charter)

New York                                                         65-0565144
----------------------                                   ----------------------
(State or other jurisdiction of                          (I.R.S. Employer
incorporation or organization)                              Identification No.)

3665 Bee Ridge Road, Suite 300
Sarasota, Florida                                                34233
-------------------------------                          ----------------------
(Address of principal executive offices)                       (Zip Code)

Issuer's telephone number (941) 927-7874

Securities registered under Section 12(b) of the Exchange Act:

     Title of each class                                Name of each exchange
                                                        on which registered
           None                                                  None
-----------------------------------                  ---------------------------

Securities registered under Section 12(g) of the Exchange Act:

                          Common Stock, $.001 par value
                       -----------------------------------
                                (Title of class)

Copies of Communications Sent to:

                              Mercedes Travis, Esq.
                              Mintmire & Associates
                              265 Sunrise Avenue, Suite 204
                              Palm Beach, FL 33480
                              Tel: (561) 832-5696; Fax: (561) 659-5371


<PAGE>



     Indicate by Check  whether the issuer (1) filed all reports  required to be
filed by Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or
for such shorter  period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.

                   Yes X        No
                      ---         ---

     As of June 30,  2001,  there are  20,022,889  shares of voting stock of the
registrant issued and outstanding, all of which have voting rights.














<PAGE>



                                     PART I

Item 1. Financial Statements


Condensed Consolidated Balance Sheets                                 F-1

Condensed Consolidated Statements of Operations                       F-2

Condensed Consolidated Statements of Cash Flows                       F-3

Notes to the Financial Statements                                     F-5















<PAGE>



<TABLE>
<CAPTION>
                         SURGICAL SAFETY PRODUCTS, INC.

                            CONDENSED BALANCE SHEETS



                                                              (Unaudited)
                                                                  June                  December
                                                                  30,                      31,
                                                                  2001                    2000
                                                            ----------------        -----------------
<S>                                                        <C>                     <C>
                  Assets

Current Assets
  Cash                                                     $           3,767       $           52,247
  Accounts receivable                                                      -                    8,022
  Employee advances                                                        -                    1,500
  Certificates of deposit                                                  -                   50,000
  Prepaid expenses                                                     6,600                   26,409
  Assets held for sale                                                27,600                   27,600
                                                            ----------------        -----------------
    Total current assets                                              37,967                  165,778
                                                            ----------------        -----------------

Property and equipment, net                                                -                   71,973
                                                            ----------------        -----------------

Other Assets
  Intangible assets, net                                              42,782                   44,278
  Software development costs, net                                     23,851                   26,629
  Investments                                                          9,750                    9,750
  Deposits                                                                 -                    4,645
                                                            ----------------        -----------------
    Total other assets                                                76,383                   85,302
                                                            ----------------        -----------------




Total Assets                                               $         114,350       $          323,053
                                                            ================        =================
</TABLE>



<PAGE>




<TABLE>
<S>                                                        <C>                     <C>
                                                               (Unaudited)
                                                                  June                   December
                                                                   30,                     31,
                                                                  2001                     2000
                                                             ---------------         ----------------

Liabilities and Stockholders' Equity

Current Liabilities
  Line of credit                                           $          45,945        $         100,000
  Deferred revenue                                                    30,602                  177,875
  Notes payable - related parties                                     41,563                   35,063
  Notes payable - bridge loan                                         81,000                        -
  Accounts payable and accrued expenses                              459,592                  451,561
    Total current liabilities                                        658,702                  764,499
                                                             ---------------         ----------------

Long-Term Liabilities
   Notes payable                                                     351,081                  842,795
    Total Liabilities                                              1,009,783                1,607,294
                                                             ---------------         ----------------


Stockholders' Equity
  Common stock, $.001 par value,
    10000,000 shares authorized;
    20,022,889 and 14,865,373 shares issued
    and outstanding in 2001 and 2000, respectively                    20,022                   14,866
  Common stock held in escrow                                              -                   (1,365)
  Additional paid-in capital                                       4,449,862                3,841,398
  Accumulated deficit                                             (5,365,317)              (5,139,140)
    Total stockholders' equity                                      (895,433)              (1,284,241)
                                                             ---------------         ----------------

Total Liabilities and Stockholders' Equity                 $         114,350        $         323,053
                                                             ===============         ================
</TABLE>


                     The accompanying notes are an integral
                       part of these financial statements.


                                       F-2


<PAGE>




<TABLE>
<CAPTION>
                       CONDENSED STATEMENTS OF OPERATIONS
                THREE AND SIX MONTHS ENDED JUNE 30, 2001 AND 2000
                                   (UNAUDITED)

                                                   Six Months Ending June 30,         Three Months Ending June 30,

                                                   2001              2000                     2001         2000
                                              --------------   -----------------    --------------    --------------
<S>                                          <C>              <C>                   <C>              <C>
Revenue                                      $       185,839  $          459,725            74,480   $       324,069
                                              --------------   -----------------    --------------    --------------

Costs and expenses
  Cost of revenues                                    18,093              23,372             3,562             7,339
  Operating expenses                                 301,653             751,306           112,778           415,588
  Research and development expenses                        -              33,181                 -            18,837
  Interest expense                                    20,297             211,697             7,773            30,276
  Loss on disposal/impairment of assets               71,973                   -             1,597                 -
                                              --------------   -----------------    --------------    --------------
    Total costs                                      412,016           1,019,556           125,710           472,040
                                              --------------   -----------------    --------------    --------------

Net loss                                     $      (226,177) $         (559,831)          (61,230)  $      (147,971)
                                              ==============   =================    ==============    ==============

Net loss per share                           $        (0.015) $           (0.047)           (0.004)  $        (0.012)
                                              ==============   =================    ==============    ==============
</TABLE>









                     The accompanying notes are an integral
                       part of these financial statements.


                                       F-3



<PAGE>



<TABLE>
<CAPTION>
                         SURGICAL SAFETY PRODUCTS, INC.
                            STATEMENTS OF CASH FLOWS
                    SIX MONTHS ENDING JUNE 30, 2001 AND 2000
                                   (UNAUDITED)


                                                                       2001                     2000
                                                                 -----------------         ---------------
<S>                                                            <C>                       <C>
Cash Flows From Operating Activities
  Net loss                                                     $          (226,177)       $       (559,831)
                                                                 -----------------         ---------------
  Adjustments to reconcile net loss to cash
    used in operating activities
       Depreciation and amortization                                         4,274                 125,698
       Common stock issued for services and
            employee compensation                                           84,150                       -
       Stock option compensation expense                                         -                   4,682
       Accrued interest added to notes payable                              21,066                  37,663
       Loss on disposal/impairment of assets                                71,973
       Interest expense - convertible debt                                       -                 167,143
       Decrease (increase) in operating assets
         Receivables                                                         9,522                (297,047)
         Inventory                                                               -                       -
          Prepaids and other                                                24,454                  51,715
       Increase (decrease) in operating liabilities
         Accounts payable and accrued expenses                              27,031                (238,920)
         Deferred revenue                                                 (147,273)                      -
           Total adjustments                                                95,197                (149,066)
                                                                 -----------------         ---------------
             Net cash used in operating activities                        (130,980)               (708,897)
                                                                 -----------------         ---------------

 Cash Flows From Investing Activities
   Furniture and equipment purchased                                             -                 (21,549)
   Proceeds from bridge loan                                                81,000                       -
   Software development additions                                                -                (119,981)
     Net cash used in investing activities                                  81,000                (141,530)
                                                                 -----------------         ---------------

 Cash Flows From Financing Activities
   Proceeds/(repayments) - related party loans                               6,500                 (15,000)
   Advances/(repayments) on line of credit, net                             (5,000)                      -
   Loan costs                                                                    -                 (70,000)
   Proceeds from notes payable                                                   -                 650,000
   Proceeds from issuance of common stock                                        -                       -
     Net cash provided by financing activities                               1,500                 565,000
                                                                 -----------------         ---------------

 Net increase (decrease) in cash                                           (48,480)               (285,427)
 Cash at beginning of year                                                  52,247                 516,799
 Cash at end of year                                           $             3,767       $         231,372
                                                                 =================         ===============
</TABLE>





<PAGE>






<TABLE>
<S>                                                            <C>                       <C>
                                                                           2001                   2000
                                                                 --------------         --------------
Supplemental Cash Flow Information:
  Cash paid for interest                                       $          3,000       $          5,783
                                                                 ==============         ==============
</TABLE>





For purposes of the statement of cash flows,  management  considers all deposits
and financial  instruments with original maturities of less than three months to
be cash and cash equivalents.

Material  non-cash  transactions  not  reflected in the  statement of cash flows
include:

For the Six Months Ended June 30, 2001

-    Certificate of deposits pledged against the line of credit were used to pay
     down the line of credit in the amount of $50,000

-    Common  stock and  additional  paid in capital of  $103,150  was issued for
     accrued salaries and salaries expense in the amount of $19,000 and $84,150,
     respectively

-    Common stock and additional  paid in capital of $511,836 was issued for the
     conversion of notes payable

For the Six Months  Ended June 30, 2000

-    Deferred financing costs of $231,385 related to the issuance of warrants in
     conjunction with the issuance of notes payable in March 2000

-    Common stock and additional  paid in capital of $226,759 was issued for the
     conversion of notes payable





                     The accompanying notes are an integral
                       part of these financial statements.

                                       F-4



<PAGE>



Note 1 - Accounting Policies
Basis of Presentation

The  condensed  financial  statements  of Surgical  Safety  Products,  Inc.  and
Subsidiary (Company) have been prepared without audit, pursuant to the rules and
regulations of the Securities and Exchange  Commission.  Certain information and
footnote  disclosures,  normally  included in financial  statements  prepared in
accordance  with  U.S.  generally  accepted  accounting  principles,  have  been
condensed or omitted pursuant to such rules and regulations.  These consolidated
financial   statements  should  be  read  in  conjunctions  with  the  financial
statements  and notes thereto  included in the  Company's  Annual Report on Form
10-KSB for the year ended December 31, 2000.

The results of  operations  for the three and six month  periods  ended June 30,
2001 are not necessarily  indicative of the results to be expected for any other
period or for the full year.

In the opinion of Company's  management,  the accompanying  unaudited  financial
statements  contain  all  adjustments,  consisting  of only  normally  recurring
adjustments,  necessary to present  fairly the  financial  positions of June 30,
2001,  the  results  of  operations  and cash flows for the three and six months
ended June 30, 2001 and June 30, 2000.

Reclassifications

Certain   reclassifications  have  been  made  in  the  prior  year's  financial
statements to conform to the current period presentation.

Net Loss Per Share

Net loss per share has been computed in accordance  with  Statement of Financial
Accounting  Standards (FASB) No. 128, "Earnings Per Share," by dividing net loss
by the weighted average number of shares outstanding  during the period.  Common
stock  equivalents have not been included in the computation of weighted average
number of shares outstanding since the effect would have been anti-dilutive.

Note 3 - Impairments

During the first half of fiscal year 2001, the Company's management examined the
book  value  of  all  the  assets  held  by  the  Company.  As a  result  of the
examination,  all  property  and  equipment  not held for sale was written  off.
Accordingly,  the  Company  recorded an  impairment  loss of $71,973 for the six
months ended June 30, 2001.


                                       F-5


<PAGE>


Note 4 - Long Term Debt

On February 7, 2001,  the  investment  banking  firm which held the  outstanding
notes  payable as of December 31,  2000,  converted  $230,000 of  principal  and
$18,570 of accrued interest to 662,854 shares of the Company's common stock at a
conversion  price of $0.375 per share.  In  addition,  on  February  7, 2001 the
Company executed a loan cancellation and settlement agreement effectively ending
the  line-of-credit  agreement with the  investment  banking firm which held the
notes payable as of December 31, 2000.  Pursuant to the  agreement,  on April 3,
2001 the lender  converted an  additional  $243,665 of principal  and $19,601 of
accrued interest to 702,043 shares of the Company's common stock at a conversion
price of $0.375  per share.  As of June 30,  2001 the  principal  balance of the
amount owed to the lender was $316,335,  plus accrued interest of $34,746. Until
fully converted,  the remaining balance will accrue interest at 8% annually.  In
accordance with the agreement the lender has turned over all escrowed shares and
has committed to convert the remaining principal and accrued interest as soon as
possible.




                                       F-6


<PAGE>



Item 2. Management's Discussion and Analysis of Results of Operations.

General

     The Company's (OTC BB: SSPD) overall mission is the research,  development,
production and distribution of innovative  products and services for healthcare.
Consisting  of both  traditional  products and  innovative  business-to-business
e-solutions,  the  common  goal is a safer and more  efficient  environment  for
healthcare workers,  manufacturers and patients.  Originally formed as a medical
device company,  Surgical shifted focus to being an e-company when the Company's
management recognized an untapped market niche:  responding to the critical need
for immediate communication and access to information in healthcare.

     During the last  quarter,  the Company has been  relatively  inactive as it
prepares  for the  acquisition  of all of the  shares of C5 Health  Inc.  by its
wholly owned  subsidiary,  OIX, Inc. Upon  completion of such  transaction,  the
Company  anticipates that it will operate two divisions  providing  products and
services to the medical industry and operate C5's current businesses.  C5 Health
has two divisions;  C5 Media Enterprises and C5 Health commerce.  Surgical's two
divisions  are  the  Information  Systems  Division,  formerly  referred  to  as
Oasis@work,    through   its   Oasis   Information    Exchange   that   provides
business-to-business  on-demand  safety and  efficiency  driven  e-business  and
information  for  healthcare  workers  and the  Medical  Products  and  Services
Division that develops, manufactures and distributes medical devices.

About Oasis Information Exchange

     The Oasis  Information  Exchange ("OIX") strategy is healthcare  e-business
content  aggregation  and  applications  integration  through a virtual  private
network.  It links the entire healthcare  continuum,  which includes  healthcare
workers,   administration,   patients,   and   healthcare   and   pharmaceutical
manufacturers.  Oasis Information Exchange is a true healthcare data center with
multiple  access  points.  It  is  an  Internet-based  virtual  private  network
consisting of points-of-access via intranets, the Internet, internet appliances,
and through  TouchPorts  located  throughout  healthcare  facilities  across the
country.  Although the Company is now focusing on providing its services through
the  Internet,   TouchPorts   remain   available  as  an  alternative   and  are
user-friendly   touch-access   internet   appliances   which  allow   healthcare
professionals  access to high quality  clinical  reference  and agency  mandated
information services.

     OIX consists of three lines of e-business.  The primary product produced by
OIX is a service that creates customized training applications for virtually any
topic. These web browser-based  educational  modules are designed to provide the
end-user with succinct,  current information on any topic within practically any
industry.  As a second  line of  business,  OIX builds  on-line  communities  in
specific target markets positioned as information  exchanges.  The third line of
business,  a  natural  by-product  of the first  two,  is  Internet  application
development and support services

     During  the third  quarter of 2000,  the  Company  realized  that they were
focusing too much attention on the installation of hardware rather than focusing
its  attention  on its real  product  -  information.  Due to the  increase  and
availability of PC's and Internet  accessibility  in the heathcare  environment,
the Company  realizes that, while in some cases its OASiS network is needed in a
particular  environment,  by an large,  its  larger  market is for its  content.
Essentially  the  Company  changed  from  a  hardware  network  supplier  to  an
information  broker  which will  create an  information  exchange  network for a
defined  healthcare  community  that links the  end-users to the industry  while
adding value to both parties. This is essentially what the Company was doing all
along;  however,  it had focused on the delivery  system for its product  rather
than the product itself.


<PAGE>



     In 2000,  the Company  negotiated a new agreement  with the  Association of
Peri-Operative  Registered Nurses ("AORN"). This agreement was terminated in the
fall of 2000.  The Company  currently  is  negotiating  a new  arrangement.  The
previous  agreement is expected to be based on shared revenues rather than usage
fees. The overall purpose of the new agreement is related to OIX, Inc. providing
services to AORN and its constituency,  in exchange for support and affiliations
with AORN and other industry entities.

     The Company  expects to generate  revenue from  sponsorships  of the CD and
from user fees and advertising on its website.  The Company negotiated its first
sponsorship  agreement with US Surgical in lieu of the previous  agreement which
required massive expenditures for hardware installations. A number of additional
corporate content providers also have been added as clients,  including Stryker,
Storz, Haemacure and others.

     The Company  plans to scale the concept for other niche markets by creating
websites  that  cater to a  particular  speciality.  The  Company  will focus on
providing website and intranet development.

         SutureMate(R)

     SutureMate(R),  a  patented,   disposable,   surgical  assist  device,  was
initially   introduced  in  1993.  Its  unique  design  facilitates  the  highly
recommended  one-handed  suturing  technique  which is advocated by occupational
safety experts.  When one-handed  suturing is not used, extra steps are required
by the surgeon or the  assistant in cutting the needle free of the suture thread
and extra time and hand  movements  are  required  of the  surgeon  in  manually
adjusting  needles  while  using a needle  holder  in most  suturing  processes.
SutureMate(R)  allows  the  surgeon  to use a safer,  more  efficient  method of
surgical   stitching.   The  product   has   features   which   include  a  foam
needle-cushion, and a suture cutting slot.

     SutureMate(R)  was re-designed in late 1998 and has been re-released  since
demand has increased due to statutory changes relating to needlestick  injuries.
Legislation has been adopted at both the federal and state level. An overview of
state needle safety legislation can be viewed at www.cdc.gov/niosh/ndl-law.html.
This legislation  essentially  requires state agencies with employees at rist to
implement needleless systems and sharps with engineered sharps injury protection
in order to prevent the spread of bloodborn pathogens in the workplace.

     The product was  re-engineered  and updated after  feedback from over 4,000
surgeons and surgical  technologists  who used or reviewed the product since its
inception.  As a result of the re- design,  the Company  believes that there are
new clinical  advantages and that the product can be produced at a significantly
lower manufacturing cost. These beliefs are based on the fact that the re-design
includes  a  tent-like  configuration  with a hidden  cutting  device  contained
between the  adhesive  base and the holding  device.  This allows the surgeon to
separate  the needle from the suture  without a scrub nurse  intervening  with a
scissor.  The cost reduction will result from the fact that the original version
cost  approximately  $6.00 per unit while the new  version  costs  approximately
$1.10 per unit including packaging and sterilization, allowing it to be marketed
in the $5 to $6 range which is more in keeping  with  pricing  for a  disposable
product. Due to its acceptance by user and quality standards, SutureMate(R) is a
"proven" product that complies with current legislation.

     On  Feb  13,  2001,  the  Company   announced  an  agreement  with  DeRoyal
Industries,  Inc. ("DeRoyal")to distribute  SutureMate(R) worldwide.  DeRoyal is
the largest  privately held healthcare  supplier of safety devices with over 250
sales  representatives  worldwide.  Formed in 1973,  DeRoyal is a international,
vertically-integrated supplier of institutional and consumer healthcare products
and


<PAGE>



services,  with 27  subsidiaries  and  affiliates  in seven states  (California,
Florida,  Georgia,  Oklahoma,  South Carolina,  Tennessee, and Virginia) and ten
countries (Canada, Costa Rica, England,  Estonia,  Germany,  Ireland, Italy, the
Netherlands, Sweden and the United States). DeRoyal's four business units, Acute
Care, Patient Care, Wound Care and OEM (original equipment manufacturer) produce
more than 25,000  products,  including:  rehabilitation  and  therapy  products,
sports  medicine  supports,  orthopedic  bracing and  supports,  fiberglass  and
plaster  casting;  wound care dressings;  unitized  surgical  delivery  systems,
including TracePak and custom procedural trays; surgical accessories;  neonatal,
labor  and  delivery   products;   angiographic,   endoscopic,   anesthesia  and
temperature  monitoring products; as well as manufacturing services in plastics,
textiles,  electrical  manufacturing,   converting  and  sterilization.  DeRoyal
introduced the re-designated SutureMate(R) at AORN in March, placed an order for
8,000 units for which the  Company  was paid when it made  delivery in May 2001.
DeRoyal carries  SutureMate(R)  in its surgical safety  assessory line, which is
being highly promoted in the current environment of blood borne pathogen concern
and increased safety legislation.

     Currently,  the  re-designed  SutureMate(R)  is  manufactured by the Hansen
Plastic  Division of Tuthill  Corporation  at their plant located in Clearwater,
Florida  ("Tuthill").  The  Company is  continuing  the  process of  negotiating
additional manufacturing sources and original equipment manufacturer sales.

Corporate Developments

     The Company  entered into an agreement with IBM Global  Services  effective
January 3, 2000 which included an IBM Customer Agreement and a Statement of Work
(the "IBM Global  Agreement").  Under the terms of the IBM Global  Agreement IBM
agreed to provide  complete  implementation  and support  service  solutions for
1,200 OASiS terminals in an estimated 400 end user locations during the 12 month
period commencing December 1, 1999. On February 3, 2000, IBM Global Services and
the Company  finalized the Statement of Work.  The services to be provided under
the agreement  included project  planning,  site surveys,  product  acquisition,
network design,  web-site hosting  services,  premises  wiring,  OASiS TouchPort
Implementation,  help desk support and consulting  services.  The estimated cost
for performing the work was approximately $10 million.  In addition,  IBM Global
Services  agreed to bill the Company a monthly  service  charge for pre and post
installation support services, including 24-7 support, and for labor, travel and
out of pocket  expenses.  The Company  was to provide  technical  resources  and
oversee the IBM Global's activities.  Due to the new Internet focus, the Company
chose to pursue for the  delivery of its  product,  there was no longer any need
for the services to be provided by IBM.  Effective July 14, 2000,  this contract
was  terminated.  In March 2001, IBM brought suit against the Company.  See Part
II, Item 1. "Legal Proceedings."

     Effective June 7, 2000, the Company's line of credit with SouthTrust in the
amount of $100,000 was renewed through August 12, 2000, with an option to extend
the maturity  until  October 15, 2000 if the Company  pledged a  certificate  of
deposit in the amount of $25,000.  The interest  rate is prime plus 1.5% and the
line is secured by the Company's equipment,  receivables and inventory. The line
is guaranteed  personally by Dr. Swor. The line of credit was renewed on October
15, 2000 and the maturity date is December 31, 2000. The outstanding  balance at
such time was $100,000. The Company pledged an additional $25,000 certificate of
deposit to secure the line. As of December 31, 2000, the outstanding balance was
$100,000.  In the first half of 2001,  the Company  paid down the line of credit
with the two (2) pledged  certificates of deposit and $5,000 in cash. As of this
date a balance of $50,945  remains  outstanding and the Company is in default on
the terms of the agreement.  the Company paid off the  outstanding  balance plus
accrued interest in through terms agreed to July 27, 2001.


<PAGE>



     Effective  July 1, 2000,  the Company  entered into an agreement  with AORN
under  which  AORN  will  provide  certain  of  its  proprietary  content  on  a
non-exclusive  license basis to the Company.  Under the  agreement,  AORN was to
deliver to the  Company  certain of its content for which it agreed to grant the
Company a  non-exclusive  license  to market and  promote.  The  Company  was to
receive a substantial  credit toward  advertising  in the AORN Journal and other
AORN publications. The Company was required to provide the software and hardware
to promote and market the AORN content.  In January 2001,  AORN gave the Company
notice of termination.  The agreement  required 180 days notice and provided for
refund,  but the Company  continues to  negotiate  with AORN on this and further
business such as on-line  products  directories.  Following  the C5 merger,  the
Company anticipates  completing  negotiations on a new arrangement that is based
upon shared revenue.

     In  December  1999,  the Company  executed a Loan  Agreement  with  Thomson
Kernaghan & Co.,  Ltd.  ("TK"),  as Agent and Lender,  whereby TK agreed to make
loans to the Company of up to $5,000,000 in installments for a period commencing
with the date of the  agreement  and ending on  November  30, 2002 (the "TK Loan
Commitment").  The Company may request additional draws of no less than $500,000
provided its Common  Stock has traded for a minimum of $1.00 for 20  consecutive
days and the stock has had an average  trading  volume of 25,000  shares for the
same period.  Due to the Company's  current share price, it does not qualify for
additional draws at this time.  Under the terms of the TK Loan Commitment,  each
installment  is supported by a convertible  note and security  agreement and the
Agent and Lender are granted warrants to purchase shares of the Company's Common
Stock.  Further,  2,700,000  shares are held by TK in escrow  for the  potential
conversion  under the notes or exercise of the warrants.  Under the terms of the
TK Loan Agreement, an initial loan of $650,000 was made on December 30, 1999. On
March 31, 2000 the Company received a second installment under the TK Commitment
in the amount of $650,000.  On April 28, 2000, TK elected to convert $100,000 of
outstanding  principal and $2,630 of the accrued  interest into shares of Common
Stock at a price of $0.5625 per share which represents  182,453 shares.  On June
9, 2000, TK elected to convert  $120,000 of outstanding  principal and $4,129 of
the accrued  interest into shares of Common Stock at a price of $0.375 per share
which represents 331,010 shares. On July 11, 2000, TK elected to convert $40,000
of  outstanding  principal and $1,683.13 of the accrued  interest into shares of
Common Stock at a price of $0.375 per share which represents  111,155 shares. On
October 24, 2000, TK elected to convert  $250,000 of  outstanding  principal and
$16,219 of the accrued interest into shares of Common Stock at a price of $0.375
per share which represents  709,918 shares.  The Company granted TK registration
rights  and was  obligated  to file a Form S-3  within  sixty  (60)  days of the
agreement.  The Company filed a  registration  statement on Form S-3 on March 2,
2000 covering  initially  20,038,097 shares of its Common Stock. The issuance of
the  securities  was made  pursuant  to  Regulation  S of the Act.  The Form S-3
registration  statement  was declared  effective  on April 11,  2000.  Since the
Company did not meet  financial  projections  which were an integral part of the
transaction,  TK and the Company  re-negotiated the arrangement which terminated
the Loan Commitment and settled all matters between the parties.

     Pursuant to a loan cancellation and settlement agreement effective February
7, 2001 (the "Cancellation Agreement"),  TK agreed to convert the balance of the
December 1999 debt in the amount of $140,000 plus accrued and unpaid interest in
the amount of $12,395 and to convert $90,000 on the  installment  given on March
31, 2000 under the Loan  Commitment  plus accrued and unpaid  interest of $6,175
into a total of 662,854  shares of the Common Stock  registered  by the Form S-3
registration,  thereby leaving an outstanding  principal balance dating to March
31, 2000 of $560,000  plus accrued and unpaid  interest  (the "March  Balance").
Interest  on the March  Balance  shall  continue  to accrue at the rate of eight
percent (8%) per annum;  however, all future interest payments, at the option of
the Company, may be made in cash or by delivery of registered shares at


<PAGE>



a  conversion  price  equal per share  equal to the amount of accrued and unpaid
interest as of the  conversion  or  repayment  date  divided by the five (5) day
average closing bid price prior to the conversion or repayment date. Further, TK
committed,  subject to not exceeding  ownership of 4.99%,  to convert as soon as
possible the March Balance. The Company may continue to repay all or any part of
the March  Balance in cash.  TK agreed to return  all shares  held in escrow and
agreed to a triangular  merger then  contemplated by the Company.  Provided such
merger  occurred  before  May 15,  2001,  TK  agreed  not to sell,  directly  or
indirectly,  more than twenty-five  percent (25%) of the Company's volume in any
trading day.  Such  anticipated  merger did not occur  before May 15,  2001.  In
consideration of the Cancellation  Agreement and the accelerated conversion into
the  Company's  shares,  the  Company  agreed  to issue  682,108  shares  of its
restricted  Common  Stock in relation to the balance of the  December  1999 debt
which was  converted  and  3,109,487  shares of its  restricted  Common Stock in
relation to the March 31, 2000  installment as bonus shares (the "Bonus Shares")
Additionally,  the Company granted,  for a period of two years,  both the Lender
and the  Agent  each  warrants  to  purchase  380,000  shares  of the  Company's
restricted Common Stock at $0.1846 per share (the "Bonus Warrants"). Until fully
converted,  TK was given the option to place an  independent  third party on the
Company's Board of Directors.  Of the 20,038,097  shares registered on Form S-3,
only those shares issued pursuant to the earlier conversions and pursuant to the
agreement and original  Lender and Agent Warrants  would be registered  with the
balance  deemed  null and void.  Accordingly,  the  registration  of  13,255,946
potentially  issuable  registered  shares would be null and void and such shares
would not be issued .

     Following  execution  of the  Cancellation  Agreement,  on April 2, 2001 TK
converted an  additional  $243,665 of principal on the March Balance and accrued
and unpaid interest in the amount of $19,601 into a total of 702,043 shares. The
certificate  for shares held in escrow was cancelled and there are no longer any
escrowed shares in relation to the arrangements  between the parties.  As of the
date hereof, the principal  indebtedness to TK is in the amount of $316,335 plus
accrued and unpaid interest from March 31, 2000.

     Until fully converted,  the TK Loan Commitment,  as interest accrues,  will
increase  the long term debt of the Company.  The Company is  currently  seeking
other potential funding. With the TK Loan Commitment and in the event additional
debt is raised,  the Company will incur  future  interest  expense.  The TK Loan
Commitment,  if fully converted and all warrants are exercised,  will dilute the
interest of existing  shareholders and in the event additional equity is raised,
management  may be  required to dilute the  interest  of  existing  shareholders
further or forego a substantial interest in revenues,  if any. In the event that
the Company is successful in securing  additional debt financing,  the amount of
such  financing,  depending upon its terms,  would increase  either the short or
long term debt of the Company or both.

     In December 2000, the Company formed a Florida  corporation,  OIX Inc. as a
wholly owned subsidiary. The Officers and Directors of Surgical serve in similar
capacities with OIX Inc.

     In February 2001, the Company executed a Term Sheet with Emagisoft  whereby
Emagisoft was to merge into OIX,  Inc..  The  shareholders  of Emagisoft were to
exchange  their  shares for share in Surgical on a 1 for 1 basis.  In  addition,
Emagisoft's  Preferred  Shares were to be exchanged  their  preferred  shares in
Surgical's  Preferred Shares on a 1 for 1 basis. The reverse  triangular  merger
was expected to be completed some time in May 2001;  however,  due to a shortage
of  funds  on the  part  of both  Emagisoft  and  Surgical  the  merger  was not
completed.

     Surgical  entered into a new Term Sheet with C5 Health Inc.  ("C5") on July
10,  2001  whereby C5 will  merge into OIX,  Inc.  The  shareholders  of C5 will
exchange their shares for share


<PAGE>



in Surgical on a 1 for 1 basis. The reverse  triangular merger is expected to be
completed as soon as all  statutory  meeting  requirements  and  securities  law
considerations are completed.

     On May 22, 2001, C5 acquired  assets from Millenium  Health  Communications
Inc. including furniture and fixtures, computer equipment, and approximately 315
domain names. C5's principal business is transaction-based healthcare e-business
and information services. C5 operates  Health24News.com and Salud.com,  Internet
websites  that  provide  healthcare  information,  the first in English  and the
second in Spanish,  MediTrader.com,  a web-based asset  maximization tool and C5
Scheduler, a web-based access management solution.

     Surgical has been seeking a merger  partner  since the last quarter of 2000
and  particularly  is seeking  qualified  management  to oversee  the day to day
operations  of  the  Company.  During  the  negotiations  for  the  merger  with
Emagisoft,  three (3) former members of Surgical's  Board of Directors  resigned
effective  June 1, 2001.  At the time of the merger  with C5,  three new members
nominated  by C5 will  gone the  Surgical  board and a  seventh  member  will be
selected by such  reconstituted  board to serve until the next annual meeting of
the shareholders.

     Effective  June 1,  2001,  the  Board  of  Directors  passed  a  resolution
regarding  the  employment  arrangement  with Dr.  G.  Michael  Swor.  The Board
resolved  that such  arrangement  be for a period of five (5) years at an annual
salary of  $100,000  per year.  Said  salary may be  accumulated  by Dr. Swor if
necessary and may be converted into shares of the Company's  Common Stock at his
election.  For the first year,  said salary may be  converted at 75% of the fair
market value on June 1, 2001. The salary for each subsequent year is convertible
at 75% of the fair market value on June 1 of such year. In addition, during each
year,  Dr. Swor will receive a  performance  bonus equal to 10% of the Company's
earnings before taxes, which bonus is payable quarterly.  This performance bonus
may be  accumulated  as well and is convertible on the same basis as the salary.
Dr.  Swor  also was  granted  a right of first  refusal  to match  the terms and
conditions of any legitimate offer to purchase the assets of the Company made by
an independent third party. Dr. Swor will receive  customary  benefits as may be
available to other  employees.  Lastly,  Dr. Swor was granted the opportunity to
convert  all  accrued  but unpaid  salary due him  through  May 31,  2001 at the
closing bid price on June 1, 2001. Dr. Swor's accrued but unpaid salary amounted
to $93,150 and this was converted  into  4,657,500  shares of restricted  Common
Stock based upon the applicable price on June 1, 2001.

     Effective June 1, 2001, the Board of Directors passed a further  resolution
awarding  500,000  shares of its  restricted  Common Stock to the acting  office
manager  in  consideration  of her past and  future  efforts  on  behalf  of the
Company. Said shares were valued at $10,000.

Discussion and Analysis

     The  Company  was  founded  in 1992  to  combat  the  potential  spread  of
bloodborne pathogenic infections such as HIV and hepatitis. It has broadened its
mission to  research,  develop,  manufacturing,  marketing  and selling  medical
products and services to the healthcare community.

     The  Company  was in  the  development  stage  until  1993  when  it  began
commercial  shipments of  SutureMate(R),  its first  product.  From inception in
June,  1992  through  December  31,  2000,  the  Company  generated  revenues of
approximately  $1,876,000  from a limited number of customers.  Since  inception
through  December  31,  2000,  the Company has  generated  cumulative  losses of
approximately  $5,140,000.   Although  the  Company  experienced  a  significant
percentage  growth in revenues from fiscal 1992 to fiscal 2000, the Company does
not believe prior growth rates are indicative of future  operating  results.  At
the current time, the Company is


<PAGE>



relatively  inactive  while the  merger  with C5 is  completed.  There can be no
assurance that  profitability  or significant  revenues on a quarterly or annual
basis will occur in the future.  Moreover,  the  Company  expects to continue to
incur operating losses through at least through fiscal 2001, and there can be no
assurance that losses will not continue after such date.

     As discussed in the independent  auditors' report for the fiscal year ended
December 31, 2000,  the  operating  losses  incurred by the Company  raise doubt
about its ability to continue as a going concern. Until the completion of the C5
merger,  the Company does not expect to  experience  any growth.  At the current
time, reduced operations are being funded by bridge loans and residual sales and
the Company's net loss is likely to continue,  although at a reduced level while
awaiting the merger. This inactive period is causing a significant strain on the
Company's  management,  financial and other resources.  The Company's ability to
manage any possible future growth, should it occur, will depend on a large part,
upon  completion of the C5 merger.  There can be no assurance  that  significant
problems in completing this merger will not occur.  Any failure to complete this
merger within a reasonable amount of time will have a material adverse effect on
the Company's  business,  financial  condition and results of  operations.  As a
result of the difficulty in forecasting  revenue levels,  the Company expects to
continue to experience significant fluctuations in its revenues, costs and gross
margins, and therefore its results of operations.

     The Company's  plan of operations for the next twelve months is to complete
the merger with C5 and thereafter to focus on building  revenue from  production
of its web-enabled  training  applications called Trainlets that it is currently
marketing to healthcare companies and the other products and services offered by
both companies.

     In this  regard,  the Company  executed a term sheet with C5 under which C5
will merge into the Company's wholly owned subsidiary OIX, Inc.  Surgical and C5
decided to proceed with merger plans  because there are certain  synergies  that
are expected to result from the merged  companies.  The merger is anticipated to
bring additional  management and operations support, as well as access to growth
capital and synergistic  product lines related to  transaction-based  healthcare
e-business,  high- traffic  healthcare  website portals and proprietary  medical
websites and physician practice management software.  It is anticipated that the
existing infrastructure and management of C5 can provide the depth and stability
in management Surgical has been seeking to improve over the last few years. As a
result of these  features,  management  for these two  companies  believed  that
collectively  they could  achieve the goals of each of the companies at a faster
rate  and  that  the  combined  companies  will be more  attractive  to  outside
financial sources..

     The Company  estimates  that  revenues  will be  sufficient to fund ongoing
operations at the current level when the current  websites are fully  functional
and its  registered  user base reaches  levels of 50,000 or more. The Company is
also aggressively  marketing its web-enabled  Trainlets to healthcare  companies
for which it has already received contracts totaling approximately $323,000.

     In the short term, to fund operations  through fiscal 2001, the Company has
been seeking  additional funds from strategic  alliances with potential clients,
its shareholders, from additional third party financing or seek third party debt
or  equity  financing  other  than  those  planned  by the  current  anticipated
agreements.  At the current time,  there are three (3) employees of the Company,
Anthony Palmer,  the CTO, Dr. Swor and Ms. Sherman who are providing the ongoing
management tasks during this period of reorganization.

     As discussed in Note 21 to the  Financial  Statements  for the period ended
December  31,  2000,  if the  financing  referred to above is not  secured,  the
recoverability of the recorded asset amounts may be impaired.


<PAGE>



     Earlier In 2001,  the  Company  had  required  between $5 and $8 million in
additional capital in the form of debt or equity to fund the continued expansion
of the  Oasis  system  and its  development  to  meet  increased  demand  and to
implement its plans for increased  marketing of its medical device products.  It
is  anticipated  that with the  merger of C5 into  OIX,  Inc.,  the needs of the
company will be reduced to $2-5 Million because the synergistic benefits of both
companies'  products and services should enhance revenue  production and provide
economies of scale to reduce expenses and gain new business.  Also, C5 brings an
established physical plant, which includes a fully integrated NT Network, e-mail
hosting,  web hosting and internal web development  capability.  There can be no
assurance that any long-term  financing will be available to the Company or that
it will be on terms that the Company may seek.

Results of Operations for the Six Months Ended June 30, 2001 and 2000

Overview

     From its inception, the Company has incurred losses from operations.  As of
June 30, 2001,  the Company had  cumulative  net losses  totaling  approximately
$5,365,000. During fiscal 2000, management shifted its focus to the marketing of
its proprietary  products,  especially those  associated with Oasis  Information
Exchange.  Currently,  the  Company  is  relatively  inactive  and  is  awaiting
completion of the merger of C5 with its wholly owned subsidiary, OIX, Inc.

Financial Position

     As of June 30, 2001,  2000, the Company had a deficit of working capital of
$620,735,  as compared to a working  capital of $275.724 at June 30, 2000.  This
increase in deficit is primarily due to management  recording an impairment loss
on assets combined with larger payable balances.

Revenues

     For the six months  ended June 30,  2001 and 2000,  the  Company  had total
revenues of $185.839  and $ 459.725,  respectively.  Revenues for the six months
ended June 30, 2001 consist of sale of SutureMate(R) and recognition of deferred
revenue.  For the six months  ended June 30,  2000,  revenues  were derived from
primarily from license and production fees.

Selling, General, and Administrative Expenses

     For the six months ended June 30,  2001,  operating  expenses  decreased by
$449,743  or 59%  from$751,306  for the six  months  ended June 30,  2000.  This
decrease is  primarily  related to relative  inactive  status and  reduction  of
operations while awaiting the C5 merger.

     In the past,  the  Company  has  focused on the design and  development  of
proprietary  products.  For  fiscal  2001,  the  Company  planned  to  launch an
aggressive  marketing plan that was designed to increase  worldwide sales of its
products;  however,  such plan was suspended  while the Company engaged in first
its  attempt  to merge  Emagisoft  in OIX,  Inc.  and now with its plans for the
merger of OIX, Inc. with C5.

Liquidity and Capital Resources

     The financial  condition,  liquidity  and capital  resources of the Company
should be assessed  in context  with the ability of the Company to continue as a
going concern as discussed in the  independent  auditors'  report for the fiscal
year ended December 31, 2000.


<PAGE>



     The  Company's  operations  have been  funded  primarily  from cash flow of
approximately  $87,500  from  bridge  loans and loans from  related  parties.  A
significant  amount of those funds were expended on merger related  ventures and
joint  operations  with  Emagesoft.  This  allowed the  Company to continue  its
essentially inactive operations while now awaiting the C5 merger.

     The company had a line of credit with  SouthTrust in the amount of $100,000
that was renewed  through August 12, 2000, with an option to extend the maturity
until October 15, 2000 if the Company  pledged a  certificate  of deposit in the
amount  of  $25,000.  The  interest  rate was  prime  plus 1.5% and the line has
secured by the Company's  equipment,  receivables  and  inventory.  The line was
guaranteed personally by Dr. Swor. The line of credit was renewed on October 15,
2000 and the maturity  date was December 31, 2000.  The  outstanding  balance at
such time was $100,000. The Company pledged an additional $25,000 certificate of
deposit to secure the line. As of December 31, 2000, the outstanding balance was
$100,000.  In the first half of 2001,  the Company  paid down the line of credit
with the two (2) pledged certificates of deposit and $5,000 in cash. As of July,
2001,  the  Company  has paid off the line of credit  and all  accrued  interest
through a settlement agreement with Southtrust Bank.

     Net cash used for  investing  for the six months  ended  June 30,  2001 was
approximately  $  $81,000,   representing   primarily  bridge  loans  and  joint
operational capital from Imagesoft.

     In the short term, to fund  operations  through the balance of fiscal 2001,
the Company will seek additional  funds from strategic  alliances with potential
clients,  its shareholders,  from additional third party financing or seek third
party  debt  or  equity  financing  other  than  those  planned  by the  current
agreements. Additionally, the Company anticipates that revenues will continue to
be generated from the sale of SutureMate(R)  and that such revenues will help to
fund  the  current  level  of  relatively  inactive  operations.  Provided  that
additional funding is secured, the Company believes that it can meet its capital
needs  through  year end.  There can be no  assurance  that the Company  will be
successful in these efforts.

Forward-Looking Statements

     This Form 10-QSB includes  "forward-looking  statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities  Exchange  Act of  1934,  as  amended.  All  statements,  other  than
statements of historical  facts,  included or  incorporated by reference in this
Form 10-QSB which address  activities,  events or developments which the Company
expects or anticipates will or may occur in the future, including such things as
future capital  expenditures  (including the amount and nature thereof),  demand
for the Company's  products and services,  expansion and growth of the Company's
business and operations, and other such matters are forward-looking  statements.
These  statements  are based on certain  assumptions  and  analyses  made by the
Company in light of its  experience  and its  perception of  historical  trends,
current conditions and expected future  developments as well as other factors it
believes are appropriate in the circumstances.  However,  whether actual results
or developments will conform with the Company's  expectations and predictions is
subject  to a number of risks and  uncertainties,  general  economic  market and
business  conditions;  the business  opportunities (or lack thereof) that may be
presented  to and pursued by the  Company;  changes in laws or  regulation;  and
other   factors,   most  of  which  are  beyond  the  control  of  the  Company.
Consequently, all of the forward-looking statements made in this Form 10-QSB are
qualified by these cautionary  statements and there can be no assurance that the
actual results or  developments  anticipated by the Company will be realized or,
even if substantially  realized, that they will have the expected consequence to
or effects on the Company or its business or operations.



<PAGE>



PART II

Item 1.  Legal Proceedings.

     On March 13, 2001,  the Company was served with a Summons and  Complaint by
IBM in an action  entitled  International  Business  Machines v. Surgical Safety
Products  Inc.  (The  "Action").  The Action was brought in the Circuit Court in
Sarasota  Florida.  In the Action,  IBM has  brought  four (4) causes of action,
namely,  breach  of  contract,  implied  contract,  account  stated  and  unjust
enrichment.  Each cause of action relates to the contract  between  Surgical and
IBM  relative to the delivery of services  and  equipment.  Surgical had entered
into the arrangement  with IBM to meet its  commitments to US Surgical.  When US
Surgical  failed to perform as  expected,  Surgical  sought  termination  of the
arrangement  with IBM.  Effective July 14, 2000,  this contract was  terminated.
Surgical has been working with IBM in an effort to settle this matter.  Surgical
has filed an answer denying the allegations,  interposing  affirmative  defenses
and has filed  counterclaim  against IBM for an accounting of funds paid to IBM.
IBM has answered the  counterclaim  and  interposed  affirmative  defenses.  The
litigation is in the  discovery  stage.  IBM is seeking  payment of in excess of
$600,000 for invoices  principally related to software and labor associated with
implementing the US Surgical  Agreement.  Should IBM prevail in this Action,  it
would have a material adverse effect upon Surgical's  financial  condition.  The
Company  believes  it has an absolute  defense to the breach of  contract  claim
since the agreement  provided that the Company could  terminate and provided the
payments required for such termination.  Further the agreement required that the
Company  approve  all work  prior to  performance  and the work for which it was
invoiced was not approved. The implied contract and unjust enrichment claims can
only go forward  if the there is no valid  contract  since they are  alternative
pleadings.  The Company  believes that it has just and  meritorious  defenses to
this action.

     The Company knows of no other legal  proceedings  to which it is a party or
to which any of its property is the subject,  which are pending,  threatened  or
contemplated or any unsatisfied judgments against the Company.

Item 2. Changes in Securities and Use of Proceeds

     There were no changes in the Company's securities in the quarter ended June
30, 2001.

Item 3.  Defaults in Senior Securities

         None

Item 4. Submission of Matters to a Vote of Security Holders.

     No matters were  submitted  to the  Security  Holders for a vote during the
quarter ended June 30, 2001.

Item 5. Other Information

         None

Item 6.  Exhibits and Reports on Form 8-K



<PAGE>



     (a) The exhibits  required to be filed  herewith by Item 601 of  Regulation
S-B, as described in the following index of exhibits, are incorporated herein by
reference, as follows:

<TABLE>
<CAPTION>
Exhibit No.             Description
-------------------------------------------------------------------------------
<S>            <C>
3.(I).1        Articles of Incorporation of Surgical Safety Products, Inc., a Florida corporation filed
               May 15, 1992 [1]

3.(I).2        Articles of Amendment filed December 9, 1992 [1]

3.(I).3        Articles of Amendment filed July 19, 1994 [1]

3.(I).4        Articles of Amendment filed October 11, 1994 [1]

3.(I).5        Articles of Incorporation of Sheffeld Acres, Inc., a New York Corporation filed May
               7, 1993 [1]

3.(I).6        Articles of Merger filed in the State of Florida October 12, 1994 [1]

3.(I).7        Certificate of Merger filed in the State of New York February 8, 1995 [1]

3.(I).8        Certificate to Do Business in the State of Florida filed April 11, 1995 [1]

3.(I).9        Certificate of Amendment filed May 1, 1998 [1]

3.(I).10       Certificate of Amendment filed February 28, 2000 [7]

3.(II).1       Bylaws of Sheffeld Acres, Inc., now known as Surgical Safety Products, Inc. [1]

3.(II).2       Amended Bylaws of Surgical Safety Products, Inc. [2]

10.1           Acquisition of Endex Systems, Inc. d/b/a/ InterActive PIE dated December 8, 1997
               [1]

10.2           Prepaid Capital Lease Agreement with Community Health Corporation relative to
               Sarasota Medical Hospital OASiS Installation dated January 30, 1998 [1]

10.3           Letter of Intent with United States Surgical Corporation dated February 12, 1998 [1]

10.4           Form of Rockford Industries, Inc. Rental Agreement and Equipment Schedule to
               Master Lease Agreement [1]

10.5           Ad-Vantagenet Letter of Intent dated June 19, 1998 [1]

10.6           Distribution Agreement with Morrison International Inc. dated September 30, 1996
               [1]

10.7           Distribution Agreement with Hospital News dated August 1, 1997 [1]
</TABLE>



<PAGE>


<TABLE>
<S>            <C>
10.8           Clinical Products Testing Agreement with Sarasota Memorial Hospital dated January
               30, 1998 [1]

10.9           Real Estate Lease for Executive Offices effective June 1, 1998 [1]

10.10          Employment Agreement with Donald K. Lawrence dated April 1, 1997 [1]

10.11          Employment Agreement with G. Michael Swor dated June 15, 1998 [1]

10.12          Employment Agreement with Frank M. Clark dated June 15, 1998 [1]

10.13          Agreement for Consulting Services with Stockstowatch.com Inc. dated March 30,
               1988 [1]

10.14          Form of Employee Option Agreement dated July 1994 [1]

10.15          Form of Employee Option Agreement dated 1998 [1]

10.16          Form of Consultants Option Agreement dated July 1994 [1]

10.17          Form of Consultants Option Agreement dated 1998 [1]

10.18          Confidential Private Offering Memorandum dated May 30, 1995 [1]

10.19          Supplement to Private Offering Memorandum dated October 30, 1995 [1]

10.20          Stock Option Agreement with Bay Breeze Enterprises LLC dated April 9, 1998 [1]

10.21          Revolving Loan Agreement, Revolving Note, Security Agreement with SouthTrust
               Bank dated May 2, 1997 [1]

10.22          Agreement between the Company and T. T. Communications, Inc. dated October 15,
               1998 [2]

10.23          Agreement between the Company and U.S. Surgical Corporation dated October 28,
               1998. [2]

10.24          Collaborative Agreement between the Company and Dr. William B. Saye dated
               November 16, 1998. [2]

10.25          Kiosk Information System, Inc. Purchase Order dated November 3, 1998 [2]

10.26          Surgical Safety Products 1999 Stock Option Plan adopted January 1999 [2]

10.27          Form of the Employee Option Agreement under the Surgical Safety Products 1999
               Stock Option Plan dated January 1999 [2]

10.28          Form of the Director, Consultant and Advisor Option Agreement under the Surgical
               Safety Products 1999 Stock Option Plan dated January 1999 [2]

10.29          Verio, Inc. Access Service Agreement dated February 16, 1999. [2]
</TABLE>


<PAGE>


<TABLE>
<S>            <C>
10.30          Form of Investor Subscription Documents and Agreements relative to the April 1999
               Self Directed Private Placement Offering under Rule 506 of Regulation D. [3]

10.31          Form of the Warrant issued pursuant to the April 1999 Self Directed Private
               Placement Offering under Rule 506 of Regulation D. [3]

10.32          Consulting Agreement dated April 1999 with Koritz Group, LLC. [3]

10.33          Agreement dated April 1999 with KJS Investment Corporation. [4]

10.34          Agreement dated May 1999 with Ten Peaks Capital Corp. [4]

10.35          Private Partner Network Agreement dated July 30, 1999 with US Surgical [5]

10.36          Staff/Client Leasing Agreement dated October 16, 1999, as amended September 15,
               1999 [5]

10.37          Agreement dated July 15, 1999 with Triton Capital Inc.[6]

10.38          Effective December 30, 1999, Loan Agreement, Note, Security Agreement, Lender's
               Warrant, Agent's Warrant, Registration Rights Agreement and Escrow Agreement
               relative to the December 1999 transaction with Thomson Kernaghan & Co., Inc.  and
               Amendment thereto. [7]

10.39          Effective January 3, 2000 IBM Customer Agreement and Statement of Work. [7]

10.40          Investment Banking Services Agreement dated February 2, 2000 with Dunwoody
               Brokerage Services Inc. [8]

10.41          Consulting Agreement dated February 15, 2000 with Global Development Advisors
               Inc. [8]

10.42          Surgical Safety Products 2000 Stock Option and Award Plan [8]

10.43          Agreement with Steel Beach Productions dated February 29, 2000 [9].

10.44          Agreement with Horizon Marketing Group dated May 16, 2000 [10]

10.45          Agreement with EPIX dated May 25, 2000 [10]

10.46          Amendment to the Company's 2000 Stock Option and Awards Plan dated June 6,
               2000 [10]

10.47          Revolving Loan Agreement, Revolving Note, Security Agreement with SouthTrust
               Bank dated June 7, 2000 [10]

10.48          Agreement with AORN effective July 1, 2000 [10]

10.49          Agreement with Carver Cross dated July 6, 2000 [10]

10.50          Agreement with U.S. Surgical effective June 28, 2000 [11]
</TABLE>


<PAGE>


<TABLE>
<S>            <C>
10.51          Agreement with Imagyn dated September 18, 2000 [12]

10.52          Agreement with Haemacure dated September 19, 2000 [12]

10.53          Agreement with Storz dated September 29, 2000 [12]

10.54          Agreement with Quantum dated October 6, 2000 [12]

10.55          Agreement with Stryker dated October 9, 2000 [12]

10.56          Property Lease dated October 13, 2000 [12]

10.57          Agreement with GDA dated October 25, 2000 [12]

10.58          Loan Cancellation and Settlement Agreement with Thomson Kernaghan & Co.  Ltd.
               effective February 7, 2001 [13]

10.59          Term Sheet for merger with Emagicsoft Technologies Inc.  dated February, 2001 [13]

10.60          Selective HR Solutions Agreement dated March 2001. [13]

10.61          DeRoyal Industries, Inc.  Agreement dated 2001 [13]

13.1           Definitive Proxy Statement filed February 28, 2000 [8]
--------------
</TABLE>


[1]  Previously filed with the Company's Form 10SB

[2]  Previously filed with the Company's Amendment No. 1 to the Form 10SB

[3]  Previously  filed with the Company's Form 10QSB for the Quarter ended March
     30, 1999

[4]  Previously  filed with the Company's  Form 10QSB for the Quarter ended June
     30, 1999

[5]  Previously filed with the Company's Amendment No. 2 to the Form 10SB

[6]  Previously  filed  with the  Company's  Form  10QSB for the  Quarter  ended
     September 30, 1999

[7]  Previously filed with the Company's Form S-3 on March 2, 2000.

[8]  Previously  filed with the  Company's  Form 10KSB for the fiscal year ended
     December 31, 1999.

[9]  Previously  filed with the Company's Form 10QSB for the Quarter ended March
     31, 2000.

[10] Previously  filed with the Company's  Form 10QSB for the Quarter ended June
     30, 2000.

[11] Previously  filed with the Company's  Amendment 3 to the Form 10QSB for the
     Quarter ended June 30, 2000.



<PAGE>



[12] Previously  filed  with the  Company's  Form  10QSB for the  Quarter  ended
     September 30, 2000.

[13] Previously  filed with the  Company's  Form 10KSB for the fiscal year ended
     December 31, 2000.

     (b) No  Reports on Form 8-K were filed  during the  quarter  ended June 30,
2001.





<PAGE>



                                   SIGNATURES

      In accordance with Section 12 of the Securities Exchange Act of 1934, the
registrant caused this Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized.


                              Surgical Safety Products, Inc. (Registrant)

Date: August 14, 2001         By: /s/ Dr.  G.  Michael Swor
                              ---------------------------------------
                              Dr.  G.  Michael Swor
                              President